Acquisition Synergy Zogenix was acquired by UCB in 2022, aligning their rare disease portfolio with a larger global pharma platform. Sales opportunities exist in cross-selling UCB’s distribution channels and leverages Zogenix’s FINTEPLA relevance in LGS within broader UCB patient access initiatives.

Rare Disease Focus Specialization in rare disease therapies, notably FINTEPLA for Lennox-Gastaut syndrome, suggests targeting clinicians and payers focused on high-impact, specialty products. Potential partnerships with specialty pharmacies, patient advocacy groups, and orphan drug programs could expand market access.

Emerging Market Potential Market data shows growing demand for needle-free drug delivery systems, indicating potential for collaboration on delivery innovations or co-development initiatives that complement Zogenix’s injectable/biologic therapies within UCB’s safety and patient experience investments.

Financial Leverage With revenue in the mid tens of millions and substantial funding backing, there is room to explore strategic partnerships or joint ventures to expand commercialization, clinical programs, or expanded indications for FINTEPLA while optimizing cost of sales and access programs.

Global Distribution Located in Emeryville and part of a global corporate entity, Zogenix/UCB can leverage international sales networks, regulatory expertise, and recombinant manufacturing capabilities to accelerate market access in Europe and other regions where rare disease therapies have growing payer support.